Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537293 | 0.85 | KMT2A (0.40) | ADRB3KMT2A | |
| SCHEMBL15744671 | 0.81 | BCHE (0.38) | ADRB3MAPK1 | |
| SCHEMBL15744663 | 0.81 | SYK (0.36) | ADRB3MAPK1 | |
| SCHEMBL15744672 | 0.80 | PPARA (0.40) | ADRB3GLAMAPK1 | |
| SCHEMBL8835699 | 0.79 | GLA (0.55) | KMT2AGLACA1CA2NAMPT | |
| SCHEMBL15744891 | 0.78 | MAPK1 (0.36) | ADRB3MAPK1 | |
| SCHEMBL2843187 | 0.75 | KMT2A (0.57) | KMT2A | |
| SCHEMBL4495406 | 0.74 | CYP4F2 (0.56) | KMT2AGLACA1CA2PTGER4 | |
| SCHEMBL6676358 | 0.72 | CA2 (0.44) | KMT2AGLACA1CA2 | |
| SCHEMBL14987242 | 0.72 | NQO2 (0.46) | KMT2AGLACA1CA2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2926121-B1 | MULTI-LAYER DEVICE FOR SELECTIVELY DETERMINING MAGNESIUM ION | OPTI MEDICAL SYSTEMS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9360474-B2 | Multi-layer device for selectively determining magnesium ion | OPTI MEDICAL SYSTEMS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9360474-B2 | Multi-layer device for selectively determining magnesium ion | OPTI MEDICAL SYSTEMS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20140147876-A1 | MULTI-LAYER DEVICE FOR SELECTIVELY DETERMINING MAGNESIUM ION | IDEXX LABORATORIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140147876-A1 | MULTI-LAYER DEVICE FOR SELECTIVELY DETERMINING MAGNESIUM ION | IDEXX LABORATORIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147876-A1 | MULTI-LAYER DEVICE FOR SELECTIVELY DETERMINING MAGNESIUM ION | ORAI1, CACYBP, CASR | ADRB3 4078/4885KMT2A 3348/4885GLA 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.